HekeTiss SA, founded as a spin-off from the University Hospitals of Geneva and the University of Geneva, focuses on developing innovative medical solutions for chronic wound healing. Based in Little Switzerland, North Carolina, the company manufactures medical and dental instruments with a core mission to enhance patient care through advanced therapies. Their flagship product, TrophiPatch, is a cellular patch engineered from adipose-derived stem cells that mimics real skin and promotes faster wound healing.
Notable individuals affiliated with HekeTiss include leading researchers from the University of Geneva and University Hospitals of Geneva. The company has attracted significant interest from investors in the medical technology sector due to its groundbreaking approach to chronic ulcer treatment. HekeTiss has achieved recognition for reducing treatment times with TrophiPatch, positively impacting patients suffering from chronic ulcers worldwide.
